• ACVC Callout
News
ICViewExpert PerspectivesMedical World NewsVideosWebinars
Conference
Infection Control TodaySupplements And Featured Publications
CME/CEJob BoardPartnersSponsoredWhitepapers
Print SubscriptioneNewsletter
Educator of the Year Nomination FormEducator of the Year Official RulesEducator of the Year
Advanced Technology
Bug of the Month
COVID-19
Environmental Services
HAIs
Hand Hygiene
Long-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Prevention
Sterile Processing
Surface Disinfection
Vascular Access
Spotlight -
  • Expert Perspectives on Personal Protection Guidelines and Standardization Practices
  • Bug of the Month
Advanced Technology
Bug of the Month
COVID-19
Environmental Services
HAIs
Hand Hygiene
Long-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Prevention
Sterile Processing
Surface Disinfection
Vascular Access
    • News
    • Conference
Advertisement

Study Suggests Link Between H. pylori Bacteria and Adult Type II Diabetes

March 14, 2012
Article

A recent study shows that the presence of H. pylori bacteria is associated with elevated levels of glycosylated hemoglobin (HbA1c), an important biomarker for blood glucose levels and diabetes. This association was stronger in obese individuals with a higher Body Mass Index (BMI). The results, which suggest the bacteria may play a role in the development of diabetes in adults, are published in The Journal of Infectious Diseases and are now available online.

H. pylori infection of the stomach may be acquired in early childhood, become persistent, and can lead to gastric and duodenal ulcers; these bacteria have also been associated with an increased risk of gastric cancer. Treatment and eradication of these bacteria with antibiotics have cured many patients with ulcers, revolutionizing treatment of this disorder.

Type II diabetes causes an estimated 3.8 million adult deaths globally. There have been conflicting reports about the association between H. pylori infection and type II diabetes.  To better understand the relationship between H. pylori and the disease, Yu Chen, PhD, and Martin Blaser, MD, at NYU School of Medicine, part of NYU Langone Medical Center, cross-analyzed data from participants in two National Health and Nutrition Surveys (NHANES III and NHANES 1999-2000) to assess the association between H. pylori and levels of HbA1c. According to the study authors, H. pylori was consistently positively related to HbA1c level in adults, a valid and reliable biomarker for long-term blood glucose levels.

In addition, this association was stronger in individuals with a high BMI compared to those with a lower value. The researchers hypothesized that H. pylori may affect the levels of two stomach hormones that help regulate blood glucose, and they suggest that eradicating H. pylori using antibiotics in some older obese individuals could be beneficial. More research will be needed to evaluate the health effects of H. pylori and its eradication among different age groups and in relation to obesity status, the authors noted.

An accompanying editorial points out that while previous studies have addressed the association between type II diabetes and H. pylori in small samples, this study analyzed two independent large national samples of the general population. The editorial authors agreed with the study investigators, suggesting that adults infected with H. pylori with higher BMI levels, even if asymptomatic, may need anti-H. pylori therapy to control or prevent type II diabetes. If the study findings are confirmed, lead editorial author Dani Cohen, PhD, of Tel Aviv University in Israel, notes, they could have important clinical and public health implications.

Related Videos
Set of white bottles with cleaning liquids on the white background. (Adobe Stock 6338071172112 by zolnierek)
Medical investigators going over data. (AdobeStock 589197902 by Wasan)
CDC logo is seen on a laptop. (Adobe Stock 428450603 by monticellllo)
Association for the Health Care Environment (Logo used with permission)
COVID-19 germs, fungi, bacteria objects. (Adobe Stock 584704860 by chawalit)
Ambassador Deborah Birx, , speaks with Infection Control Today about masks in schools and the newest variant.
mRNA technology  (Adobe Stock 485886181 by kaptn)
Ambassador Deborah Birx, MD
Woman lying in hospital bed (Adobe Stock, unknown)
Related Content

Low Vaccination Concerns Highlight Need for Fall and Winter 2023 Vaccination Campaigns

September 28th 2023

Evolving Symptomatology: Respiratory Viruses in the Era of COVID-19 Variants

September 27th 2023

I’m Not Just an Infection Preventionist

September 26th 2023

Poll: What Minimum Educational Requirement Should Infection Preventionists Have?

September 25th 2023

How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2

September 25th 2023

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023

Low Vaccination Concerns Highlight Need for Fall and Winter 2023 Vaccination Campaigns

September 28th 2023

Evolving Symptomatology: Respiratory Viruses in the Era of COVID-19 Variants

September 27th 2023

I’m Not Just an Infection Preventionist

September 26th 2023

Poll: What Minimum Educational Requirement Should Infection Preventionists Have?

September 25th 2023

How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2

September 25th 2023

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023

Low Vaccination Concerns Highlight Need for Fall and Winter 2023 Vaccination Campaigns

September 28th 2023

Evolving Symptomatology: Respiratory Viruses in the Era of COVID-19 Variants

September 27th 2023

I’m Not Just an Infection Preventionist

September 26th 2023

Poll: What Minimum Educational Requirement Should Infection Preventionists Have?

September 25th 2023

How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2

September 25th 2023

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023
Related Content
Advertisement

In this photo illustration, National Foundation for Infectious Diseases logo is seen displayed on a smartphone    (Adobe Stock 346303670 By Игорь Головнёв)

Low Vaccination Concerns Highlight Need for Fall and Winter 2023 Vaccination Campaigns

September 28th 2023
Article

Cases of COVID-19, RSV, and influenza are expected to rise this fall and winter season; yet, the number of people who plan on getting the vaccines for each of the infections remains low, according to the NFID announcement today.


COVID-19 germs, fungi, bacteria objects.   (Adobe Stock 584704860 by chawalit)

Evolving Symptomatology: Respiratory Viruses in the Era of COVID-19 Variants

September 27th 2023
Article

As COVID-19 restrictions eased up, other respiratory viruses began circulating alongside SARS-CoV-2. It's crucial to identify cases and understand the symptoms of these infections to track the evolution of the virus and what health care workers should look out for.


An infection preventionist taking off her mask. (Adobe Stock, unknown)

I’m Not Just an Infection Preventionist

September 26th 2023
Article

Infection preventionists (IP) can come from many different backgrounds. This is 1 opinion from 1 very successful IP who doesn't have an RN or a BSN and the bullying that sometimes occurs.


(Adobe Stock FILE #:  56169337 by thinglass)

Poll: What Minimum Educational Requirement Should Infection Preventionists Have?

September 25th 2023
Article

Many infection preventionists (IPs) disagree on the minimum requirement to have the IP position. Let Infection Control Today know your opinion. Answer this poll, and send your thoughts to Senior Editor Tori Whitacre Martonicz at tmartonicz@mjhlifesciences.com.


Influenza, RSV, and COVID-19 (AdobeStock_249346161, AdobeStock_538653843,AdobeStock_471755796)

How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2

September 25th 2023
Article

The interaction between the respiratory viruses SARS-CoV-2, influenza, and RSV, poses ongoing challenges. Personal protective measures, testing, and vaccination are critical components of our strategy to mitigate the impact of these viruses.


weekly rounds with infection control today

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023
Article

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending September 24, 2023.

Advertise
About Us
Editorial Board
Contact Us
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News